No Data
Information on individual stocks.
Perseus <4882.T> rebounds sharply. The company has started selling the "anti-GPR87 antibody" as a new research antibody and reagent for disease research, as well as the research antibody reagent "anti-Exatecan antibody" for ADC (antibody-drug conjugate). FIXER <5129.T> has risen for three consecutive days. An agreement for capital and business collaboration has been signed with Talkable Medical (Shibuya, Tokyo). Moving forward, a full-scale entry into the medical DX (digital transformation) field will strengthen the business of Talkable Medical further.
Stocks that moved and those that were traded in the front market.
*Toyota Industries Corporation <6201> 16225 - reports suggest consideration for privatization of stocks. *Aichi Steel Corporation <5482> 8840 +1200 recognized for last period's double-digit profit increase and significant dividend increase plan this period. *Kinden Corporation <1944> 3838 +417 this period's guidance exceeds consensus. *Mitsui E&S Holdings <7003> 1857 +199 reports indicate the Trump administration's request for Japan for dual-use shipbuilding, regarded as a buying opportunity. *Anritsu Corporation <6754> 1401.5 +122 exceeds expectations.
April 28th [Today's Investment Strategy]
[Fisco Selected Stocks]【Material Stocks】Hokkan Holdings <5902> 1,699 yen (4/25) Engaged in food cans, PET bottles, and filling business. The profit forecast for the fiscal year ending March 2025 has been revised upward. The estimated operating profit is 4.5 billion yen (up 2.5% from the previous year). This is an upward revision of about 9% from the previous financial estimates, resulting in a projected increase in profit. Revenue is expected to be lower than the previous forecast, but due to cost reductions in factory expenses and Logistics costs, profit has been upwardly revised. The year-end Dividends have been set at 70 yen.
Cluster T, TIM and others.
Acquired shares of Zero Medical, which promotes the realization of SDGs and CSV management in the fields of medical care, welfare, and nursing, and fully subsidiary-ized <286A>. Cluster T has revised its upward forecast for the previous operating profit to 0.108 billion yen from 0.065 billion yen <4240>. Submitted a clinical trial application for TIMS TMS-007 (JX10) for Phase II/Phase III clinical trials in Japan <4891>.
Stocks to watch: promising domestic demand stocks with significant room for recovery.
Yukaria <286A.T> is returning to raising the possibility of supporting the management of medical institutions. While the overall market moves into a recovery phase after a sharp decline, it has potential as a quality domestic demand stock listed on the Tokyo Stock Exchange Growth Market. It supports medical institutions widely, from consulting to fundraising, lending and guaranteeing working capital, factoring of medical fee receivables, and digital transformation (DX). As demand for comprehensive management support Business increases, performance continues to grow significantly.
Yukaria [Emerging Markets Rating List]
"Morgan" <286A> Yukaria OVERWEIGHT maintained * The ratings for each company above are confirmed by us as of 03/31.